UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
__________________
FORM 8-K
CURRENT REPORT
 Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 20, 2019
THE CLOROX COMPANY
 (Exact name of registrant as specified in its charter)
__________________

Delaware		1-07151		31-0595760	
(State or other jurisdiction of	     	(Commission File Number)	     	(I.R.S. Employer	
incorporation)				Identification No.)	
1221 Broadway, Oakland, California 94612-1888
(Address of principal executive offices) (Zip code)
(510) 271-7000
 (Registrant's telephone number, including area code)
Not applicable
 (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]	  Written communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425)	
	 	
[ ]	  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
	 	
[ ]	  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
	 	
[ ]	  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	
Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading	Name of each exchange on which registered	
	Symbol(s)		
Common Stock - $1.00 par value	CLX	New York Stock Exchange	
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company     ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.
On November 20, 2019, The Clorox Company (the “Company”) held its annual meeting of stockholders in Pleasanton, California. The matters voted on and the results of the vote were as follows:

       	1.	       	The Company’s stockholders elected the following directors to each serve until the next Annual Meeting of Stockholders or until a successor is duly elected and qualified.	
 
		Number of Votes	
	     	For	     	Against	     	Abstain	     	Broker Non-Votes	
Amy Banse		88,139,990		569,951		218,124		21,069,742	
Richard H. Carmona		85,595,295		3,093,550		239,220		21,069,742	
Benno Dorer		85,233,045		3,159,541		535,479		21,069,742	
Spencer C. Fleischer		87,319,078		1,330,336		278,651		21,069,742	
Esther Lee		88,115,306		568,872		243,887		21,069,742	
A.D. David Mackay		88,331,328		330,023		266,714		21,069,742	
Robert W. Matschullat		85,735,605		2,928,324		264,136		21,069,742	
Matthew J. Shattock		88,071,571		600,545		255,949		21,069,742	
Pamela Thomas-Graham		85,531,713		3,169,072		227,280		21,069,742	
Russell Weiner		87,791,923		879,359		256,783		21,069,742	
Christopher J. Williams		88,042,111		628,369		257,585		21,069,742	
 
       	2.	       	The Company’s stockholders voted for (on an advisory basis) the approval of the compensation of the Company’s named executive officers.	
 
       	Number of Votes	
	For	     	Against	     	Abstain	     	Broker Non-Votes	
	81,851,649		6,406,875		669,259		21,070,024	
 
       	3.	       	The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2020.	
 
       	Number of Votes	
	For	     	Against	     	Abstain	     	Broker Non-Votes	
	107,970,846		1,629,225		397,736		0	

 
       	4.	       	The Company’s stockholders did not approve the proposed amendment to the Company’s Restated Certificate of Incorporation to eliminate the supermajority voting provision. Under the Company’s Restated Certificate of Incorporation, the affirmative vote of at least 80% of the outstanding voting stock is required to approve this proposal. The 87,544,878 votes in favor of this proposal represented 69.76% of the total outstanding shares of common stock.	
 
       	Number of Votes	
	For	     	Against	     	Abstain	     	Broker Non-Votes	
	87,544,878		866,508		516,679		21,069,742	

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		THE CLOROX COMPANY	
 				
Date: November 22, 2019	     	By:  	/s/ Laura Stein	
			Executive Vice President –	
 	 	 	General Counsel and Corporate Affairs